Isis Pharma earns milestone payment from Biogen

|By:, SA News Editor

Isis Pharmaceuticals (ISIS) initiates a Phase 1 study for antisense ISIS-DMPKrx, a treatment for Myotonic Dystrophy Type 1 (DM1) and earns a $14M milestone payment from Biogen Idec (BIIB). ISIS-DMPKrx is designed to reduce the production of toxic dystrophia myotonica-protein kinase RNA in cells.